{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:25:40Z","timestamp":1788852340550,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Development of Anticancer Treatments for Rare and Refractory Cancers","award":["20 pc0101051h0001"],"award-info":[{"award-number":["20 pc0101051h0001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>E7820, a sulphonamide-type anticancer agent, was developed to inhibit angiogenesis by suppressing integrin \u03b12 expression. Although early-phase trials outside Japan established 100\u00a0mg\/day as the maximum tolerated dose in monotherapy, no objective responses were observed, and further development was not planned. Subsequent studies revealed that E7820 promotes DCAF15-mediated degradation of the splicing factor RBM39 and acts as a molecular glue, providing a novel mechanism and rationale for clinical evaluation. Preclinical screening using patient-derived xenograft models demonstrated antitumour activity in biliary tract and endometrial cancers and in tumours with homologous recombination repair gene alterations. Based on these findings, the CIRCUS trial, a multicentre investigator-initiated phase I study, was initiated to assess the safety, tolerability, and preliminary efficacy of E7820 in Japanese patients with unresectable solid tumours. If the proof of concept is demonstrated in biomarker-defined cohorts, E7820 may be repositioned for selected patients, providing insights into the development of previously intractable compounds.<\/jats:p>","DOI":"10.1093\/jjco\/hyag031","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T12:56:20Z","timestamp":1771505780000},"page":"780-786","source":"Crossref","is-referenced-by-count":2,"title":["Study protocol for a phase I investigator-initiated clinical trial of E7820 in Japanese patients with unresectable solid tumours: CIRCUS trial (NCCH2303)"],"prefix":"10.1093","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5476-483X","authenticated-orcid":false,"given":"Mao","family":"Okada","sequence":"first","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-4884","authenticated-orcid":false,"given":"Chikako","family":"Funasaka","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":false,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Clinical Research Support Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Clinical Research Support Office, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Division of Molecular Pharmacology, National Cancer Center Research Institute , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2042-6829","authenticated-orcid":false,"given":"Toshihiko","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Experimental Therapeutics, National Cancer Center Hospital East , 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Mano","sequence":"additional","affiliation":[{"name":"Division of Cellular Signaling, National Cancer Center Research Institute , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,1]]},"reference":[{"key":"2026060509362162400_ref1","volume-title":"Cancer statistics in Japan 2022","author":"National Cancer Center Japan.","year":"2022"},{"key":"2026060509362162400_ref2","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1078-0432.CCR-0109-03","article-title":"An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker","volume":"10","author":"Semba","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2026060509362162400_ref3","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1078-0432.CCR-10-0010","article-title":"Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies","volume":"17","author":"Mita","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2026060509362162400_ref4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10637-016-0344-9","article-title":"A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of \u03b12 integrin inhibitor E7820 in patients with advanced solid tumors","volume":"34","author":"Milojkovic Kerklaan","year":"2016","journal-title":"Investig New Drugs"},{"key":"2026060509362162400_ref5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/nchembio.2363","article-title":"Selective degradation of splicing factor CAPER\u03b1 by anticancer sulfonamides","volume":"13","author":"Uehara","year":"2017","journal-title":"Nat Chem Biol"},{"key":"2026060509362162400_ref6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3755","article-title":"Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15","volume":"356","author":"Han","year":"2017","journal-title":"Science"},{"key":"2026060509362162400_ref7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41589-019-0378-3","article-title":"Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15","volume":"16","author":"Faust","year":"2020","journal-title":"Nat Chem Biol"},{"key":"2026060509362162400_ref8","first-page":"29","article-title":"The evolution of cancer genomic medicine in Japan and the role of the National Cancer Center Japan","volume":"21","author":"Yoshida","year":"2023","journal-title":"Cancer Biol Med"},{"key":"2026060509362162400_ref9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41698-024-00610-0","article-title":"A molecular glue RBM39-degrader induces synthetic lethality in cancer cells with homologous recombination repair deficiency","volume":"8","author":"Kohsaka","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"2026060509362162400_ref10","volume-title":"CTCAE v5.0 resources","author":"National Cancer Institute DoCTaD"},{"key":"2026060509362162400_ref11","volume-title":"e. Common terminology criteria for adverse events v5.0 Japanese translation JCOG version [CTCAE v5.0\/MedDRA v20.1 (Japanese: MedDRA\/J v25.1)]","author":"Japanese Clinical Oncology Group (JCOG)","year":"2022"},{"key":"2026060509362162400_ref12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026060509362162400_ref13","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2026060509362162400_ref14","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2014.58.4953","article-title":"Current status of single-agent phase I trials in Japan: toward globalization","volume":"33","author":"Mizugaki","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026060509362162400_ref15","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026060509362162400_ref16","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060509362162400_ref17","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N Engl J Med"},{"key":"2026060509362162400_ref18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026060509362162400_ref19","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J Pharm Pharmacol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/780\/67188487\/hyag031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jjco\/article-pdf\/56\/6\/780\/67188487\/hyag031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T13:36:32Z","timestamp":1780666592000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/56\/6\/780\/8502583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,1]]},"published-print":{"date-parts":[[2026,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyag031","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,1]]}}}